Authors
Latest:
Mass Screening for Cognitive Changes: Richard Gershon, PhDThe vice chair for research at the Northwestern University Feinberg School of Medicine discussed the potential of the mobile toolbox battery to screen hundreds of thousands for cognitive impairment.
Latest:
The Current State and Future Promise of Magnetoencephalography (MEG) in Epilepsy and BeyondMagnetoencephalography provides an opportunity for physicians to capture a more dynamic view of brain function over time and space that may offer an advantage to clinical care.
Latest:
Digital Health Tool Offers Innovative Quantitative Fall Assessment Solution for Older AdultsFalls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.
Latest:
Safety Profile of CT1812 and Its Effect on Proteomic Biomarkers of Alzheimer Disease: Mary Hamby, PhDThe vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]
Latest:
AUPN Leadership Minute Episode 36: Faculty RetentionEpisode 36 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and David G. Standaert, MD, PhD, of the University of Alabama at Birmingham. [WATCH TIME: 4 minutes]
Latest:
Simple Dizziness or Something Serious?Igor Rybinnik, MD, associate professor in the division of stroke and neurocritical care in the department of neurology at Rutgers Robert Wood Johnson Medical School, talked about aspects of dizziness.
Latest:
The Aducanumab Saga and the Future of Antiamyloid Monoclonal AntibodiesThe journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
Latest:
Appropriate Steps Needed for Integration of Biosimilars in MS Treatment Paradigm: Barry Singer, MDThe director and founder of The MS Center for Innovations in Care provided thoughts on the potential role of biosimilars in treating multiple sclerosis and the steps needed to ensure that this integration process is safe. [WATCH TIME: 4 minutes]
Latest:
Neurosurgery and Parkinson Disease: Past, Present, and Future of Deep Brain StimulationSurgical care for PD is safe and effective, and should no longer be treated as a consideration of last resort, but as a treatment option discussed early in the disease course with the patient and their family.
Latest:
Understanding the Connection Between Alzheimer Disease Plasma Biomarkers and Gait Dysfunction: Arjun Masurkar, MD, PhD; Waijha Ahmed, MDA group of clinician researchers at NYU Langone provided insight on a study presented at AAIC 2024 looking at the correlations between quantitative gait measures and Alzheimer disease biomarkers. [WATCH TIME: 4 minutes]
Latest:
Innovative Wearables to Tackle Bladder Dysfunction in Multiple Sclerosis: Valerie J. Block, PT, DPTScThe assistant professor of neurology at UCSF Weill Institute for Neurosciences talked about a study that explored the use of commercial wearable devices to monitor and manage bladder dysfunction in multiple sclerosis. [WATCH TIME: 6 minutes]
Latest:
Vaccination and Seizure Risk in Dravet Syndrome: Veronica Hood, PhD, MSThe scientific director at the Dravet Syndrome Foundation commented on the concern associated with vaccination in this patient population, noting that investigators have not observed an exacerbated risk profile with the COVID-19 vaccines. [WATCH TIME: 2 minutes]
Latest:
A Team Approach to Asleep Deep Brain StimulationHenry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.
Latest:
Therapeutic Potential of EDG-5506 in Treating Becker Muscular Dystrophy: Joanne Donovan, MD, PhDThe chief medical officer at Edgewise Therapeutics gave an overview of the mechanism of EDG-5506, an agent in development for Becker muscular dystrophy, and its early promising clinical results to date. [WATCH TIME: 6 minutes]
Latest:
Balancing Efficacy and Safety With MS Disease-Modifying Therapies: Omar Al-Louzi, MDThe director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Latest:
Patient and Clinician Takeaways on the CognICA: Chris Kalafatis, MD, MRCPsychThe chief medical officer of Cognetivity Neurosciences outlined the benefits a new integrated assessment has for clinicians and patients with dementias and multiple sclerosis. [WATCH TIME: 4 minutes]
Latest:
Importance of Informed Patient Conversations Regarding Subcutaneous Infusion Pumps for PD: Anvi Gadani, MDThe assistant clinical professor of medicine at Medstar Georgetown University Hospital highlighted the need for clinicians to maintain informed, open-minded discussions about therapeutic options. [WATCH TIME: 2 minutes]
Latest:
Discovering Role of Complement Activation in ARIA Risk Amid Fluid Treatment Landscape: Cynthia Lemere, PhDThe professor of neurology at Brigham and Women’s Hospital provided clinical insights on her presentation at AD/PD 2025 focusing on the emerging research surrounding complement activation and its influence on amyloid-related imaging abnormalities. [WATCH TIME: 7 minutes]
Latest:
Achieving Greater Diversity in Dementia Research: A Call to ActionAchieving greater diversity in study populations is a focus of increasing scrutiny, priority, and funding in all medical research, including studies enrolling individuals on the continuum of prodromal Alzheimer disease, mild cognitive impairment, and Alzheimer disease.
Latest:
Limitations of Advanced Parkinson Disease TreatmentsPanelists discuss how limitations persist with current long-term treatment standards for Parkinson disease despite advancements in treatment options.
Latest:
Empowering Women to Develop Leadership Skills in Neurology: Lara V. Marcuse, MDThe codirector of the Mount Sinai Epilepsy Program at the Icahn School of Medicine at Mount Sinai talked about the Women in Neurology and Leadership session she spoke in at IFN 2023. [WATCH TIME: 3 minutes]
Latest:
Key Points for the Management of Multiple SclerosisStephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
Latest:
Notable Sessions to Eye Amid the 2025 ACTRIMS Forum: Véronique Miron, PhDThe John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave clinical insights on emerging, innovative tracks at the 2025 ACTRIMS Forum and how these sessions align with recent trends in the multiple sclerosis field. [WATCH TIME: 4 minutes]
Latest:
Exploring Noninvasive Brain Stimulation for Neurorehabilitation: Roy H. Hamilton, MD, MS, FAANThe professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the current research landscape, clinical challenges, and future directions for noninvasive neuromodulation techniques in neurorehabilitation. [WATCH TIME: 4 minutes]
Latest:
A Patient Perspective on Gene Therapy for Neuromuscular Diseases: Justin MoyThe second-year PhD student in bioinformatics at Boston University who lives with LAMA2 congenital muscular dystrophy talked about the potential impact and challenges of gene therapy in neuromuscular diseases. [WATCH TIME: 5 minutes]
Latest:
Exploring New Therapies for MS With Research on T-bet+ memory B Cells: Rajiv Jain, PhDAt the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]
Latest:
Highlighting Early-Stage Promising Data of AAK1 Inhibitor SAT-3247 in Duchenne Muscular Dystrophy: Phil Lambert, PhDThe chief scientific officer at Satellos Bioscience discussed phase 1 findings on SAT-3247, an oral AAK1 inhibitor, highlighting its safety, pharmacokinetics, and early translatability in Duchenne muscular dystrophy. [WATCH TIME: 7 minutes]
Latest:
Implications of Diagnosing and Misdiagnosing Multiple SclerosisAlise Carlson, MD, resident of Cleveland Clinic, details the factors and long-term effects misdiagnosing a patient with multiple sclerosis can have on their quality of life.
Latest:
CGRP Therapies as Potential First-Line Migraine Preventive Treatment: Andrew Charles, MDThe director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]
Latest:
AUPN 2022 Spring Chairs Session: Simulations for Training in NeurologyDavid G. Standaert, MD, PhD; Wolfgang Muhlhofer, MD; and Latisha Sharma, MD, share their experience in applying simulation-based learning in Neurology and will discuss the current state and future potential of this approach. [WATCH TIME: 1 hour, 25 minutes]
